Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

FibroGen, Inc. operates as a research-based pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic agents to treat serious unmet medical needs. The Company has a global approach to the development and commercialization of its products.
Website: fibrogen.com



Growth: Good revenue growth rate 55.6%, there is acceleration compared to average historical growth rates 29.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -131.7%. On average the margin is improving steadily. Gross margin is high, +53.9%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -226.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 226.3% higher than minimum and 95.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -3.0x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (0.053% of cap.)

Key Financials (Download financials)

Ticker: FGEN
Share price, USD:  (+3.3%)1.2401
year average price 2.8102  


year start price 17.4000 2023-05-23

max close price 19.1900 2023-06-05

min close price 0.3801 2023-11-10

current price 1.2401 2024-05-21
Common stocks: 93 767 000

Dividend Yield:  0.0%
Last revenue growth (y/y):  55.6%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  29.5%
Historical growth of EBITDA:  -11.4%
EV / Sales: 0.8x
Margin (EBITDA LTM / Revenue): -131.7%
Fundamental value created in LTM:
Market Cap ($m): 116
Net Debt ($m): 14
EV (Enterprise Value): 130
Price to Book: -0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-06Seeking Alpha

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

2024-03-20InvestorPlace

3 Nightmare Nasdaq Stocks Not Worth Holding Another Day

2023-11-06Seeking Alpha

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

2023-11-06Zacks Investment Research

FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

2023-10-19InvestorPlace

7 Stocks to Sell Before the Axe Falls

2023-08-30Zacks Investment Research

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

2023-08-30Proactive Investors

FibroGen stock plummets as muscular dystrophy drug trial fails

2023-08-30Market Watch

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

2023-08-16Zacks Investment Research

Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround

2023-08-07Seeking Alpha

FibroGen, Inc. (FGEN) Q2 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FGEN FGEN FGEN FGEN FGEN FGEN FGEN
reportedCurrency USD USD USD USD USD USD USD
cik 921 299 921 299 921 299 921 299 921 299 921 299 921 299
fillingDate 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-05-06 16:10:42 2024-02-26 16:11:28 2023-11-06 16:11:19 2023-08-07 16:11:39 2023-05-08 16:12:01 2023-02-27 16:29:53 2022-11-07 16:12:17
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 56M 27M 40M 44M 36M 34M 16M
costOfRevenue 26M 5M 4M 6M 3M 5M 4M
grossProfit 30M 22M 36M 39M 33M 29M 11M
grossProfitRatio 0.539 0.801 0.894 0.871 0.903 0.857 0.726
researchAndDevelopmentExpenses 38M 52M 61M 95M 74M 62M 75M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 23M 24M 26M 31M 34M 34M 30M
otherExpenses 0 5M 0 0 0 0 0
operatingExpenses 61M 76M 87M 127M 109M 96M 105M
costAndExpenses 87M 81M 91M 132M 112M 101M 109M
interestIncome 3M 2M 4M 3M 1M 924 000 2M
interestExpense 5M 5M 5M 3M 2M 1M 84 000
depreciationAndAmortization 820 000 2M 2M 3M 1M 4M 2M
ebitda -30M -52M -47M -85M -75M -63M -92M
ebitdaratio -0.541 -1.928 -1.161 -1.927 -2.076 -1.820 -5.838
operatingIncome -31M -54M -63M -88M -76M -66M -94M
operatingIncomeRatio -0.556 -1.997 -1.582 -1.987 -2.104 -1.925 -5.952
totalOtherIncomeExpensesNet -2M -3M -13M -417 000 -1M -195 000 2M
incomeBeforeTax -33M -57M -64M -88M -77M -66M -92M
incomeBeforeTaxRatio -0.599 -2.092 -1.600 -1.996 -2.141 -1.931 -5.843
incomeTaxExpense 33 000 80 000 84 000 -235 000 74 000 108 000 114 000
netIncome -33M -56M -64M -88M -78M -66M -92M
netIncomeRatio -0.589 -2.072 -1.585 -1.978 -2.143 -1.934 -5.850
eps -0.330 -0.570 -0.650 -0.900 -0.820 -0.710 -0.980
epsdiluted -0.330 -0.570 -0.650 -0.900 -0.820 -0.710 -0.980
weightedAverageShsOut 99M 98M 98M 98M 95M 94M 94M
weightedAverageShsOutDil 99M 98M 98M 98M 95M 94M 94M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FGEN FGEN FGEN FGEN FGEN FGEN FGEN
reportedCurrency USD USD USD USD USD USD USD
cik 921 299 921 299 921 299 921 299 921 299 921 299 921 299
fillingDate 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-05-06 16:10:42 2024-02-26 16:11:28 2023-11-06 16:11:19 2023-08-07 16:11:39 2023-05-08 16:12:01 2023-02-27 16:29:53 2022-11-07 16:12:17
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 106M 114M 121M 153M 189M 156M 156M
shortTermInvestments 72M 122M 130M 183M 167M 266M 253M
cashAndShortTermInvestments 178M 236M 251M 336M 356M 422M 409M
netReceivables 66M 41M 32M 26M 18M 16M 15M
inventory 27M 42M 41M 41M 42M 40M 40M
otherCurrentAssets 8M 13M 40M 9M 14M 4M 10M
totalCurrentAssets 278M 332M 364M 411M 431M 493M 474M
propertyPlantEquipmentNet 77M 81M 86M 91M 95M 100M 105M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 7M 7M 5M 6M 6M 9M 22M
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 4M 6M 6M 7M 7M 7M
totalNonCurrentAssets 88M 92M 96M 104M 108M 117M 135M
otherAssets 0 1.000 0 0 0 0 0
totalAssets 366M 424M 460M 515M 539M 610M 609M
accountPayables 4M 18M 19M 13M 71M 31M 19M
shortTermDebt 16M 14M 12M 11M 10M 10M 12M
taxPayables 7M 7M 8M 6M 8M 8M 8M
deferredRevenue 13M 13M 7M 7M 16M 13M 7M
otherCurrentLiabilities 163M 173M 171M 163M 157M 219M 214M
totalCurrentLiabilities 197M 218M 209M 194M 255M 274M 252M
longTermDebt 90M 90M 142M 145M 77M 80M 81M
deferredRevenueNonCurrent 147M 158M 154M 165M 163M 186M 200M
deferredTaxLiabilitiesNonCurrent 63M 67M 0 48M 0 0 0
otherNonCurrentLiabilities 56M 54M 70M 22M 73M 73M 272M
totalNonCurrentLiabilities 355M 368M 366M 381M 313M 338M 311M
otherLiabilities 0 1.000 0 0 0 0 0
capitalLeaseObligations 63M 67M 82M 85M 87M 90M 93M
totalLiabilities 552M 586M 576M 575M 567M 612M 563M
preferredStock 0 0 0 0 0 0 0
commonStock 995 000 988 000 983 000 982 000 966 000 942 000 939 000
retainedEarnings -1 875M -1 842M -1 786M -1 722M -1 634M -1 558M -1 492M
accumulatedOtherComprehensiveIncomeLoss -7M -7M -7M -6M -5M -6M -7M
othertotalStockholdersEquity 1 652M 1 644M 1 634M 1 625M 1 589M 1 541M 1 524M
totalStockholdersEquity -228M -204M -157M -102M -49M -21M 26M
totalEquity -186M -162M -115M -60M -29M -21M 26M
totalLiabilitiesAndStockholdersEquity 366M 424M 460M 515M 539M 610M 609M
minorityInterest 42M 42M 42M 42M 20M 20M 0
totalLiabilitiesAndTotalEquity 366M 424M 460M 515M 539M 610M 609M
totalInvestments 79M 129M 130M 189M 173M 276M 275M
totalDebt 169M 170M 154M 156M 87M 90M 93M
netDebt 63M 57M 33M 4M -102M -66M -63M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FGEN FGEN FGEN FGEN FGEN FGEN FGEN
reportedCurrency USD USD USD USD USD USD USD
cik 921 299 921 299 921 299 921 299 921 299 921 299 921 299
fillingDate 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-05-06 16:10:42 2024-02-26 16:11:28 2023-11-06 16:11:19 2023-08-07 16:11:39 2023-05-08 16:12:01 2023-02-27 16:29:53 2022-11-07 16:12:17
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -33M -56M -64M -88M -77M -66M -92M
depreciationAndAmortization 820 000 2M 2M 3M 3M 3M 3M
deferredIncomeTax 0 2M -261 000 -2M 0 0 0
stockBasedCompensation 9M 9M 9M 16M 16M 16M 16M
changeInWorkingCapital -34M 27M -35M -66M -46M -6M 22M
accountsReceivables -25M 20M -6M -9M -1M -218 000 17M
inventory 14M -176 000 432 000 -11 000 -2M 148 000 -289 000
accountsPayables -14M -1M 7M -61M 40M 11M -9M
otherWorkingCapital -10M 9M -35M 4M -83M -17M 14M
otherNonCashItems 33M -2M 2M 26M 2M 535 000 -80 000
netCashProvidedByOperatingActivities -59M -18M -85M -111M -102M -53M -52M
investmentsInPropertyPlantAndEquipment -29 000 -251 000 -684 000 -993 000 -591 000 -333 000 -865 000
acquisitionsNet 0 158M -55M 0 0 0 0
purchasesOfInvestments -9M -95M -53M -102M -2M -67M -38M
salesMaturitiesOfInvestments 60M 105M 108M 88M 107M 68M 84M
otherInvestingActivites 51M -158M 55M 656 000 0 -2000.000 2000.000
netCashUsedForInvestingActivites 51M 10M 54M -14M 103M 1M 45M
debtRepayment -12 000 -20 000 -22 000 -236 000 -172 000 -213 000 -101 000
commonStockIssued 0 45 000 0 18M 31M 1M 210 000
commonStockRepurchased -153 000 2M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -153 000 -237 000 -22 000 74M 907 000 48M -1M
netCashUsedProvidedByFinancingActivities -165 000 -246 000 -22 000 92M 31M 49M -1M
effectOfForexChangesOnCash 223 000 1M -1M -3M -526 000 2M -4M
netChangeInCash -8M -7M -32M -36M 33M -260 000 -12M
cashAtEndOfPeriod 106M 114M 121M 153M 189M 156M 156M
cashAtBeginningOfPeriod 114M 121M 153M 189M 156M 156M 168M
operatingCashFlow -59M -18M -85M -111M -102M -53M -52M
capitalExpenditure -29 000 -251 000 -684 000 -993 000 -591 000 -333 000 -865 000
freeCashFlow -59M -19M -85M -112M -102M -53M -53M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-06 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-07 11:00 ET
FibroGen to Participate in Upcoming Investor Conferences
2024-05-06 20:02 ET
FibroGen Reports First Quarter 2024 Financial Results
2024-04-29 11:00 ET
FibroGen to Report First Quarter 2024 Financial Results
2024-04-24 20:02 ET
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncol...
2024-04-02 21:46 ET
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
2024-03-26 11:00 ET
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-03-11 11:00 ET
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
2024-02-26 21:06 ET
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-26 21:05 ET
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
2024-02-20 12:00 ET
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 12:00 ET
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
2024-01-25 12:00 ET
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
2023-12-09 22:02 ET
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
2023-11-06 21:01 ET
FibroGen Reports Third Quarter 2023 Financial Results
2023-10-23 11:00 ET
FibroGen to Report Third Quarter 2023 Financial Results
2023-08-29 20:15 ET
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
2023-08-07 20:01 ET
FibroGen Reports Second Quarter 2023 Financial Results
2023-07-25 11:00 ET
FibroGen Announces Leadership Transition
2023-07-24 11:00 ET
FibroGen to Report Second Quarter 2023 Financial Results
2023-06-26 11:04 ET
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
2023-06-07 10:55 ET
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
2023-06-06 20:01 ET
FibroGen to Present at Jefferies Global Healthcare Conference
2023-05-18 11:30 ET
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
2023-05-08 20:01 ET
FibroGen Reports First Quarter 2023 Financial Results
2023-05-08 20:00 ET
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
2023-05-05 11:30 ET
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
2023-05-01 11:00 ET
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
2023-04-24 11:00 ET
FibroGen to Report First Quarter 2023 Financial Results
2023-04-17 08:50 ET
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
2023-04-03 11:00 ET
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
2023-02-27 21:01 ET
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-27 12:00 ET
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
2023-02-17 12:00 ET
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
2023-02-02 12:00 ET
FibroGen to Present at SVB Securities Global Biopharma Conference
2022-11-28 12:00 ET
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
2022-11-07 21:01 ET
FibroGen Reports Third Quarter 2022 Financial Results
2022-11-07 21:00 ET
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
2022-11-01 11:00 ET
FibroGen to Participate at Stifel 2022 Healthcare Conference
2022-10-24 11:00 ET
FibroGen to Report Third Quarter 2022 Financial Results
2022-08-26 11:00 ET
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
2022-08-08 20:01 ET
FibroGen Reports Second Quarter 2022 Financial Results
2022-07-25 11:00 ET
FibroGen to Report Second Quarter 2022 Financial Results
2022-07-01 11:00 ET
FibroGen to Participate at William Blair Biotech Focus Conference 2022
2022-06-08 11:00 ET
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
2022-05-26 11:00 ET
FibroGen to Present at Jefferies Healthcare Conference
2022-05-09 20:01 ET
FibroGen Reports First Quarter 2022 Financial Results
2022-04-25 11:00 ET
FibroGen to Report First Quarter 2022 Financial Results
2022-04-20 11:00 ET
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
2022-02-28 21:01 ET
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-14 12:00 ET
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
2022-02-04 12:00 ET
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
2022-01-04 12:00 ET
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
2021-12-20 13:00 ET
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
2021-11-09 21:01 ET
FibroGen Reports Third Quarter 2021 Financial Results
2021-11-02 11:00 ET
FibroGen to Present at Upcoming Investor Conferences
2021-10-26 11:00 ET
FibroGen to Report Third Quarter 2021 Financial Results
2021-10-25 11:00 ET
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
2021-08-25 11:00 ET
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
2021-08-19 23:35 ET
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
2021-08-19 23:30 ET
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
2021-08-16 11:00 ET
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
2021-08-11 11:00 ET
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
2021-08-09 20:01 ET
FibroGen Reports Second Quarter 2021 Financial Results
2021-07-29 11:00 ET
FibroGen to Report Second Quarter 2021 Financial Results
2021-07-19 11:00 ET
Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform
2021-07-15 22:26 ET
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
2021-07-12 11:00 ET
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
2021-06-25 13:15 ET
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
2021-06-25 12:56 ET
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
2021-06-17 11:00 ET
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
2021-06-16 12:00 ET
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
2021-05-27 11:00 ET
FibroGen to Present at Upcoming Investor Conferences
2021-05-10 20:01 ET
FibroGen Reports First Quarter 2021 Financial Results
2021-05-03 11:00 ET
FibroGen to Report First Quarter 2021 Financial Results
2021-04-28 11:00 ET
FibroGen to Present at Upcoming Investor Conference
2021-04-15 11:00 ET
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2021-04-12 11:00 ET
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2021-04-06 23:50 ET
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
2021-04-06 20:01 ET
FibroGen Provides Additional Information on Roxadustat
2021-03-16 11:00 ET
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2021-03-01 21:01 ET
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-01 21:01 ET
FibroGen Provides Regulatory Update on Roxadustat
2021-02-18 12:00 ET
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
2021-02-12 12:00 ET
FibroGen to Present at Upcoming Investor Conferences
2020-12-22 12:00 ET
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
2020-12-18 21:59 ET
FibroGen Provides Regulatory Update on Roxadustat
2020-12-02 12:00 ET
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
2020-12-01 13:00 ET
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
2020-11-27 12:00 ET
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
2020-11-27 07:02 ET
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
2020-11-06 12:00 ET
FibroGen to Present at Upcoming Investor Conferences
2020-11-05 21:01 ET
FibroGen Reports Third Quarter 2020 Financial Results
2020-10-29 11:00 ET
FibroGen to Report Third Quarter 2020 Financial Results
2020-10-22 14:08 ET
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
2020-10-14 11:00 ET
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
2020-09-08 11:00 ET
FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
2020-09-01 11:00 ET
FibroGen to Present at Upcoming Investor Conferences
2020-08-11 11:00 ET
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
2020-08-06 20:02 ET
FibroGen Reports Second Quarter 2020 Financial Results
2020-08-06 20:01 ET
FibroGen Announces New Appointments to its Board of Directors
2020-07-23 11:00 ET
FibroGen to Report Second Quarter 2020 Financial Results
2020-06-23 11:00 ET
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
2020-06-22 11:00 ET
FibroGen Appoints Thane Wettig as Chief Commercial Officer
2020-06-08 21:00 ET
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
2020-06-08 11:00 ET
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
2020-05-27 11:00 ET
FibroGen to Present at Upcoming Investor Conferences
2020-05-21 11:00 ET
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
2020-05-08 11:00 ET
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
2020-05-07 20:01 ET
FibroGen Reports First Quarter 2020 Financial Results
2020-04-24 11:00 ET
FibroGen To Report First Quarter 2020 Financial Results
2020-04-20 11:00 ET
FibroGen Reports UK Court Ruling
2020-03-02 21:01 ET
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-18 12:00 ET
FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
2020-02-11 22:00 ET
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
2020-02-11 13:00 ET
FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
2020-01-06 12:00 ET
FibroGen Names Enrique Conterno as Chief Executive Officer
2019-12-23 12:00 ET
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
2019-12-02 12:00 ET
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
2019-11-11 21:01 ET
FibroGen Reports Third Quarter 2019 Financial Results
2019-11-08 19:10 ET
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2019-11-07 21:39 ET
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease
2019-11-04 12:00 ET
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
2019-10-23 11:00 ET
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer  
2019-10-11 14:58 ET
Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019
2019-10-07 21:57 ET
FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine
2019-10-01 00:00 ET
FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat
2019-09-30 11:00 ET
FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis
2019-09-26 11:00 ET
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
2019-09-20 07:05 ET
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
2019-09-20 07:00 ET
Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
2019-04-15 11:00 ET
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2019-02-27 21:08 ET
FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-23 04:43 ET
FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

SEC forms

Show financial reports only

SEC form 10
2024-05-06 16:10 ET
FibroGen reported for 2024 q1
SEC form 8
2024-05-06 16:05 ET
FibroGen reported for 2024 q1
SEC form 8
2024-05-06 16:05 ET
FibroGen published news for 2024 q1
SEC form 10
2024-05-06 00:00 ET
FibroGen published news for 2024 q1
SEC form 10
2024-02-26 16:11 ET
FibroGen published news for 2023 q4
SEC form 8
2024-02-26 16:08 ET
FibroGen published news for 2023 q4
SEC form 8
2024-02-26 16:08 ET
FibroGen reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
FibroGen published news for 2023 q4
SEC form 10
2023-11-06 16:11 ET
FibroGen reported for 2023 q3
SEC form 8
2023-11-06 16:05 ET
FibroGen reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
FibroGen published news for 2023 q3
SEC form 10
2023-08-07 16:11 ET
FibroGen reported for 2023 q2
SEC form 6
2023-08-07 16:06 ET
FibroGen reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
FibroGen published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
FibroGen published news for 2023 q2
SEC form 6
2023-07-25 08:32 ET
FibroGen published news for 2023 q2
SEC form 6
2023-07-19 07:01 ET
FibroGen published news for 2023 q2
SEC form 6
2023-06-26 09:05 ET
FibroGen published news for 2023 q1
SEC form 6
2023-06-09 16:05 ET
FibroGen published news for 2023 q1
SEC form 6
2023-06-07 09:00 ET
FibroGen published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
FibroGen published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
FibroGen published news for 2023 q1
SEC form 10
2023-02-27 16:29 ET
FibroGen reported for 2022 q4
SEC form 6
2023-02-27 16:06 ET
FibroGen published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
FibroGen reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
FibroGen reported for 2022 q4
SEC form 10
2022-11-07 16:12 ET
FibroGen reported for 2022 q3
SEC form 6
2022-11-07 16:06 ET
FibroGen published news for 2022 q3
SEC form 10
2022-11-07 00:00 ET
FibroGen reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
FibroGen reported for 2022 q3
SEC form 10
2022-08-08 16:12 ET
FibroGen reported for 2022 q2
SEC form 6
2022-08-08 16:07 ET
FibroGen published news for 2022 q2
SEC form 10
2022-08-08 00:00 ET
FibroGen reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
FibroGen reported for 2022 q2
SEC form 6
2022-06-17 17:20 ET
FibroGen published news for 2022 q1
SEC form 6
2022-06-08 16:06 ET
FibroGen published news for 2022 q1
SEC form 10
2022-05-09 17:13 ET
FibroGen reported for 2022 q1
SEC form 6
2022-05-09 16:09 ET
FibroGen published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
FibroGen reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
FibroGen reported for 2022 q1
SEC form 6
2022-04-28 19:08 ET
FibroGen published news for 2022 q1
SEC form 6
2022-03-04 17:06 ET
FibroGen published news for 2021 q4
SEC form 10
2022-02-28 16:23 ET
FibroGen published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
FibroGen published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
FibroGen published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
FibroGen published news for 2021 q4
SEC form 10
2021-11-09 16:12 ET
FibroGen published news for 2021 q3
SEC form 6
2021-11-09 16:06 ET
FibroGen published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
FibroGen published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
FibroGen published news for 2021 q3
SEC form 6
2021-08-27 16:31 ET
FibroGen published news for 2021 q2
SEC form 6
2021-08-19 19:45 ET
FibroGen published news for 2021 q2
SEC form 6
2021-08-16 17:23 ET
FibroGen published news for 2021 q2
SEC form 6
2021-08-11 08:30 ET
FibroGen published news for 2021 q2
SEC form 10
2021-08-09 16:12 ET
FibroGen published news for 2021 q2
SEC form 6
2021-08-09 16:05 ET
FibroGen published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
FibroGen published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
FibroGen published news for 2021 q2
SEC form 6
2021-07-20 16:05 ET
FibroGen published news for 2021 q2
SEC form 6
2021-06-25 17:26 ET
FibroGen published news for 2021 q1
SEC form 6
2021-06-17 16:16 ET
FibroGen published news for 2021 q1
SEC form 6
2021-06-07 16:32 ET
FibroGen published news for 2021 q1
SEC form 6
2021-05-27 16:09 ET
FibroGen published news for 2021 q1
SEC form 6
2021-05-14 17:22 ET
FibroGen published news for 2021 q1
SEC form 10
2021-05-10 16:11 ET
FibroGen published news for 2021 q1
SEC form 6
2021-05-10 16:07 ET
FibroGen published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
FibroGen published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
FibroGen published news for 2021 q1
SEC form 6
2021-04-13 16:22 ET
FibroGen published news for 2021 q1
SEC form 6
2021-04-13 16:07 ET
FibroGen published news for 2021 q1
SEC form 6
2021-04-07 08:30 ET
FibroGen published news for 2021 q1
SEC form 6
2021-04-06 16:59 ET
FibroGen published news for 2021 q1
SEC form 10
2021-03-01 16:18 ET
FibroGen published news for 2020 q4
SEC form 6
2021-03-01 16:06 ET
FibroGen published news for 2020 q4
SEC form 6
2021-01-26 17:33 ET
FibroGen published news for 2020 q4
SEC form 6
2020-12-18 17:10 ET
FibroGen published news for 2020 q3
SEC form 6
2020-12-01 08:05 ET
FibroGen published news for 2020 q3
SEC form 6
2020-11-12 16:45 ET
FibroGen published news for 2020 q3
SEC form 10
2020-11-05 16:13 ET
FibroGen published news for 2020 q3
SEC form 6
2020-11-05 16:05 ET
FibroGen published news for 2020 q3